<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789878</url>
  </required_header>
  <id_info>
    <org_study_id>NP 779/15</org_study_id>
    <nct_id>NCT02789878</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen
      deprivation therapy with goserelin and abiraterone with or without apalutamide prior to
      radical prostatectomy for patients diagnosed with localized high-risk prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the prostate specific antigen (PSA) era, about 15% to 20% of patients are diagnosed with
      high-risk localized disease and radical prostatectomy is a standard therapy for this subgroup
      of patients. However, despite best local therapy, about 30-60% of high-risk patients will
      eventually develop biochemical relapse and a significant proportion of these patients may
      progress with metastatic disease and die from prostate cancer. Currently, there is no data
      supporting the use of neoadjuvant therapy for patients with high-risk disease since studies
      failed to demonstrate clinically significant benefit with standard androgen deprivation
      therapy (ADT). Following improved outcomes in other malignancies with the use of neoadjuvant
      therapy with active drugs in the metastatic setting, there is a growing interest in
      evaluating new-generation androgen receptor (AR)-targeted therapy in earlier stages of
      prostate cancer. Therefore, the goal of this study is to evaluate the efficacy and safety of
      neoadjuvant therapy with ADT and abiraterone versus maximal androgen blockade using ADT,
      abiraterone and apalutamide for patients with high-risk localized prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of pathologic complete response (pCR) or pathologic near complete response (pnCR), defined as less than 0,5 cm of residual tumor in the prostatectomy specimen after neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual cellularity rate</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of residual cellularity ≤ 30% in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic downgrading</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of pathologic downgrading to ≤ ypT2N0 in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA decline rate</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of PSA decline ≥ 50% and 90% after 3 months of neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive surgical margins</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of positive surgical margins in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undetectable PSA</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the rate of patients with undetectable PSA 12 months after radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Grade ≥ 3 CTCAE adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of CTCAE grade 3 or higher adverse events of the neoadjuvant therapy arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Magnetic Resonance Image Downstaging after Neoadjuvant Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the MR image downstaging after neoadjuvant therapy with pathologic analysis of the prostatectomy specimen</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory analysis to correlate tissue expression of PSA, CYP17, Ki67, and AR with pathologic response.</measure>
    <time_frame>3 months</time_frame>
    <description>To correlate the expression of PSA, CYP17, Ki67, and AR by immunohistochemistry with pCR/npCR in the prostatectomy specimen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin 10.8 mg, single dose, subcutaneously.
Abiraterone 1,000 mg, once daily, orally for 3 months.
Prednisone 5 mg, once daily, orally for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin 10.8 mg, single dose, subcutaneously.
Abiraterone 1,000 mg, once daily, orally for 3 months.
Prednisone 5 mg, once daily, orally for 3 months.
Apalutamide 240 mg, once daily, orally for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Androgen Deprivation Therapy</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>ADT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Corticosteroid</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>CYP17 inhibitor</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Androgen-receptor antagonist</description>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>ARN-509</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic confirmed prostatic adenocarcinoma

          -  Non-castrate levels of testosterone (&gt; 150 ng/dL)

          -  High-risk localized prostate cancer, defined by either:

               -  Tumor stage T3 by digital rectal examination, or

               -  Primary tumor Gleason score ≥ 8, or

               -  PSA ≥ 20 ng/mL

          -  Willing to undergo prostatectomy as primary treatment for localized prostate cancer

          -  Adequate hematologic, renal and hepatic function:

               -  WBC &gt; 3000/uL

               -  Platelets &gt; 150,000/uL

               -  Creatinine &lt; 2 mg/dL

               -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

               -  AST/ALT &lt; 2 x ULN

          -  Karnofsky Performance Status (KPS) ≥ 80%

          -  Able to swallow the study drugs whole as tablets

        Exclusion Criteria:

          -  Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of
             the prostate

          -  Current or prior hormonal therapy, radiation therapy or chemotherapy for prostate
             cancer

          -  Evidence of metastatic disease (M1) on imaging studies

          -  Other prior malignancy less than or equal to 5 years prior to randomization with the
             exception of squamous or basal cell skin carcinoma

          -  Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III
             or IV heart failure

          -  History of prior cardiac arrhythmia.

          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diogo A Bastos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diogo A Bastos, MD</last_name>
    <phone>+55 11 38932691</phone>
    <email>diogo.bastos@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariana Fiuza</last_name>
    <phone>+55 11 38932691</phone>
    <email>mariana.fiuza@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246-0000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Arai</last_name>
      <phone>+55 11 38932619</phone>
      <email>roberto.arai@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Suleima A Jokh</last_name>
      <phone>+55 11 38932617</phone>
      <email>suleima.jokh@hc.fm.usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>March 4, 2017</last_update_submitted>
  <last_update_submitted_qc>March 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>High-risk Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

